Skip to main navigation

Investor Relations

November 09, 2018

Abivax KOL event today in Paris on ABX464 therapeutic-candidate in mid-stage clinical testing for ulcerative colitis and HIV

September 28, 2018

Abivax First-Half 2018 Financial Results and Operations Update

September 04, 2018

Abivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients

July 26, 2018

Abivax Presents ABX464 Mechanism of Action Data at the 22nd International AIDS Conference (AIDS 2018)

July 25, 2018

ABIVAX secures up to EUR 20m Debt Financing from Kreos Capital